BioCentury
ARTICLE | Company News

Gruenenthal GmbH, KeyNeurotek deal

March 5, 2007 8:00 AM UTC

KeyNeurotek received exclusive, worldwide rights to develop and commercialize Grunenthal's GRT 203 to treat aconuresis (urinary incontinence) for an undisclosed amount of cash. The small molecule mu ...